Admission ferritin in STEMI predicts long-term major adverse cardiovascular outcomes
European Heart Journal Open · 01.07.2026 · 6 (4)
DOI: 10.1093/ehjopen/oeag092 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 09.06.2026. Verfasst von David Alberto Brenes-Castro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Nacional Autónoma de México, Mexico City 04510, Mexico. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Inflammation is a key driver of atherosclerosis and acute coronary syndromes (ACS). Despite the prognostic relevance of inflammatory biomarkers in STEMI, the role of serum ferritin, an inflammation-sensitive marker of iron metabolism, remains unclear. The purpose of this study is to evaluate the association between elevated ferritin (≥300 ng/mL) and long-term major adverse cardiovascular events (MACE) in patients with STEMI. Methods and results This is a substudy of the PHASE-MX registry, a prospective cohort of STEMI patients treated at our institution (2018–2021). Patients ≥18 years old with ferritin measurement at admission were included. The primary outcome was MACE [all-cause mortality, cardiogenic shock, recurrent myocardial infarction, and new-onset congestive heart failure (CHF)]. A total of 477 patients were included with a follow-up of 4.5 years (median of 533 days, IQR 338–1137). Median age was 59, 45.4% had hypertension, and 34.9% had diabetes. No differences in baseline characteristics were found among groups. Ferritin ≥300 ng/mL was present in 29.9% of patients and was associated with a higher risk of MACE (HR 1.43, 95% CI 1.06–1.94; P = 0.01), driven by all-cause mortality (HR 2.00, 95% CI 1.09–3.69) and new CHF (HR 1.46, 95% CI 1.05–2.04). This association remained significant after adjustment for inflammatory markers and GRACE score (aHR 1.48, 95% CI 1.04–2.10; P = 0.02).
Conclusion
Elevated ferritin (≥300 ng/mL) is an independent predictor of long-term MACE in STEMI, supporting its potential role as a prognostic biomarker in ACS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
- Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.
ORCID-Profile: David Alberto Brenes-Castro, Alexandra Arias-Mendoza, Diego Araiza-Garaygordobil
Zitieren
APA
Brenes-Castro, D. A., Ortega-Hernández, J. A., Latapi-Ruíz Esparza, X., Sierra-Lara Martínez, J. D., Briseno-De La Cruz, J. L., González-Pacheco, H., Gopar-Nieto, R., Arias-Mendoza, A., & Araiza-Garaygordobil, D. (2026). Admission ferritin in STEMI predicts long-term major adverse cardiovascular outcomes. European Heart Journal Open, 6(4). https://doi.org/10.1093/ehjopen/oeag092
Vancouver
Brenes-Castro DA, Ortega-Hernández JA, Latapi-Ruíz Esparza X, Sierra-Lara Martínez JD, Briseno-De La Cruz JL, González-Pacheco H, et al. Admission ferritin in STEMI predicts long-term major adverse cardiovascular outcomes. European Heart Journal Open. 2026;6(4). doi:10.1093/ehjopen/oeag092
BibTeX
@article{BrenesCastro2026,
author = {Brenes-Castro, David Alberto and Ortega-Hernández, Jorge Arturo and Latapi-Ruíz Esparza, Ximena and Sierra-Lara Martínez, Jorge Daniel and Briseno-De La Cruz, José Luis and González-Pacheco, Héctor and Gopar-Nieto, Rodrigo and Arias-Mendoza, Alexandra and Araiza-Garaygordobil, Diego},
title = {Admission ferritin in STEMI predicts long-term major adverse cardiovascular outcomes},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {4},
doi = {10.1093/ehjopen/oeag092}
}
EUVIMED